MK-677, also known as ibutamoren mesylate, is an orally active, non-peptide growth hormone secretagogue. It functions as a selective agonist of the ghrelin receptor, stimulating the pituitary gland to increase the production and release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), with minimal impact on cortisol levels
MK-677 has been explored as a potential treatment for growth hormone deficiency (GHD), including adult-onset GHD, as well as for catabolic conditions. Research has also examined its effects on bone formation and resorption, fat loss, and sleep quality improvement
Currently, no FDA-approved products contain ibutamoren mesylate. In the United States, MK-677 is classified as an Investigational New Drug and is available to researchers as a reference material
Benefits of MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, offers numerous health and wellness benefits, including:
- Improved Lean Muscle Mass and Fat Loss: Increases muscle growth, prevents muscle wasting, and boosts metabolism.
- Healthy Skeletal Frame: Enhances bone density and strength, reducing fracture risk.
- Enhanced Sleep Quality: Promotes deeper, restorative sleep by boosting growth hormone levels.
- Cognitive Function Boost: Improves memory, learning, and problem-solving skills.
- Accelerated Wound Healing: Supports tissue regeneration and speeds up recovery from injuries.
- Heart Health: Reduces bad cholesterol and protects heart cells.
- Immune System Support: Strengthens immune defenses and lowers inflammation.
- Improved Sexual Function: Enhances libido and sexual performance.
- Better Blood Sugar Control: Lowers blood sugar levels and improves insulin sensitivity.
- Improved Cholesterol Profile: Reduces bad cholesterol levels and improves lipid balance.
Key Takeaways
- What is MK-677?
MK-677 is agrowth hormone secretagogue that stimulates the pituitary gland to release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). These hormones are critical for muscle growth, fat metabolism, bone health, and more. - Advantages Over Steroids:
Unlike anabolic steroids, MK-677 is safer, does not suppress natural hormone production, and promotes muscle growth and recovery without severe side effects. - Recommended Dosage:
-
- Typical dosage: 10-25 mg daily, often taken once per day.
- For beginners: Start with a lower dose and gradually adjust.
- Always follow a doctor’s guidance for safe use.
- Safe Purchasing:
Ensure you purchase MK-677 from alegally accredited U.S. pharmacy with a prescription from a qualified doctor. This ensures quality, safety, and effective dosing tailored to your needs.
How MK-677 Works
MK-677 mimics ghrelin, a hunger hormone, and binds to growth hormone secretagogue receptors (GHSRs) in the brain. This triggers the release of growth hormone, which positively affects:
- Appetite, mood, and cognitive function.
- Sleep quality and energy levels.
- Muscle growth, fat loss, and bone density.
Research Highlights
1. Muscle Mass and Fat Loss
- Improves body composition by increasing fat-free mass and basal metabolic rate (BMR).
- Beneficial for older adults, individuals recovering from injuries, and those with muscle-wasting conditions.
2. Bone Health
- Enhances bone density by stimulating osteoblasts (bone-forming cells).
- Reduces the risk of fractures and supports faster bone repair.
3. Sleep Quality
- Increases deep sleep stages, aiding recovery and mental clarity.
- Especially effective for older adults and those with disrupted sleep patterns.
4. Cognitive Function
- Boosts memory, learning, and cognitive performance by increasing IGF-1 and supporting brain cell survival.
- May help combat age-related cognitive decline and Alzheimer’s disease.
5. Wound Healing and Tissue Repair
- Speeds up recovery by increasing collagen synthesis and enhancing cell migration to damaged tissues.
6. Heart Health
- Protects heart cells, improves cholesterol levels, and stimulates cardiac repair after injury.
7. Immune System Support
- Enhances the body’s immune response by regulating T-cells, B-cells, and cytokine production.
8. Sexual Function
- Boosts libido and sexual performance by improving hormone levels and blood flow.
9. Blood Sugar and Insulin Sensitivity
- Lowers blood sugar levels and improves the body’s response to insulin, making it beneficial for diabetics.
10. Cholesterol Balance
- Reduces low-density lipoprotein (LDL) levels, improving cardiovascular health.
Why Choose MK-677?
Discover the transformative potential of MK-677 as part of your health and fitness journey. Whether you’re aiming for:
- Enhanced muscle growth and recovery.
- Improved bone health and strength.
- Better metabolism and weight management.
MK-677 offers a science-backed solution to optimize your growth hormone levels safely and effectively. Unlock your body’s full potential today with cutting-edge peptide therapy!

References
-
- Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. doi: 10.1073/pnas.92.15.7001. PMID: 7624358; PMCID: PMC41459.
- Yoon, S., Gianturco, S., Pavlech, L., Storm, K., Yuen, M., & Mattingly, A. (2022). Ibutamoren mesylate: Summary Report. Retrieved 7 May 2022, from https://archive.hshsl.umaryland.edu/bitstream/handle/10713/14872/Ibutamoren%20mesylate_Final_2021_02.pdf?sequence=1&isAllowed=y
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998 Dec;54(12):1316-29. doi: 10.1007/s000180050257. PMID: 9893708.
- Ibutamoren – Lumos Pharma/Merck – AdisInsight. (2022). Retrieved 6 January 2022, from https://adisinsight.springer.com/drugs/800007434
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578.
- Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998 Feb;83(2):320-5. doi: 10.1210/jcem.83.2.4551. PMID: 9467534.
- Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998 Feb;83(2):362-9. doi: 10.1210/jcem.83.2.4539. PMID: 9467542.
- Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 Oct;66(4):278-86. doi: 10.1159/000127249. PMID: 9349662.
- Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999 Jul;14(7):1182-8. doi: 10.1359/jbmr.1999.14.7.1182. PMID: 10404019.
- Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res. 1998 Jul;13(7):1158-66. doi: 10.1359/jbmr.1998.13.7.1158. PMID: 9661080.
- Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7. PMID: 19015485.
- Jeong YO, Shin SJ, Park JY, Ku BK, Song JS, Kim JJ, Jeon SG, Lee SM, Moon M. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease. Int J Mol Sci. 2018 Jun 18;19(6):1800. doi: 10.3390/ijms19061800. PMID: 29912176; PMCID: PMC6032329.
- Nass, Ralf et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of internal medicine vol. 149,9 (2008): 601-11. doi:10.7326/0003-4819-149-9-200811040-00003
- Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. PMID: 21067829.
- Meyer RM, Burgos-Robles A, Liu E, Correia SS, Goosens KA. A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear. Molecular psychiatry. 2014;19(12):1284-1294. doi:10.1038/mp.2013.135.
- Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(13):4679-4684.
doi:10.1073/pnas.0305930101. - Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9.
- Welle S, Thornton C, Statt M, Mchenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996;81(9):3239-43.
- Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res. 1999;51(2):78-84.
- Welle S, Thornton C, Statt M, Mchenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996;81(9):3239-43.
- Tavares ABW, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology. 2013;2013:942030. doi:10.1155/2013/942030.
- Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.
- Weber MM. Effects of growth hormone on skeletal muscle. Horm Res. 2002;58 Suppl 3:43-8.
- Rennie M. Claims for the anabolic effects of growth hormone: a case of the Emperor’s new clothes? British Journal of Sports Medicine. 2003;37(2):100-105. doi:10.1136/bjsm.37.2.100.
- Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997;82(9):2877-84.
- Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res. 2003;60(Suppl 1):121-4.
- Norrelund H, Nair KS, Jorgensen JO, Christiansen JS, Moller N. The protein-retaining effects of growth hormone during fasting involve inhibition of muscle-protein breakdown. Diabetes. 2001;50(1):96-104.
- Adams GR.Insulin-like growth factorin muscle growth and its potential abuse by athletes. Western Journal of Medicine. 2001;175(1):7-9.
- Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.
- Christoffolete MA, Silva WJ, Ramos GV, et al. Muscle IGF-1-Induced Skeletal Muscle Hypertrophy Evokes Higher Insulin Sensitivity and Carbohydrate Use as Preferential Energy Substrate. BioMed Research International. 2015;2015:282984. doi:10.1155/2015/282984.
- Hamarneh SR, Murphy CA, Shih CW, et al. Relationship Between Serum IGF-1 and Skeletal Muscle IGF-1 mRNA Expression to Phosphocreatine Recovery After Exercise in Obese Men With Reduced GH. The Journal of Clinical Endocrinology and Metabolism. 2015;100(2):617-625.
doi:10.1210/jc.2014-2711. doi:10.1210/jc.2014-2711. - Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology. 2004;145(11):4803-5.
- Shavlakadze T, Chai J, Maley K, et al. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci. 2010;123(Pt 6):960-71.





